JP2020530777A5 - - Google Patents

Info

Publication number
JP2020530777A5
JP2020530777A5 JP2020520429A JP2020520429A JP2020530777A5 JP 2020530777 A5 JP2020530777 A5 JP 2020530777A5 JP 2020520429 A JP2020520429 A JP 2020520429A JP 2020520429 A JP2020520429 A JP 2020520429A JP 2020530777 A5 JP2020530777 A5 JP 2020530777A5
Authority
JP
Japan
Prior art keywords
domain
scfv domain
quadruspecific
binding specificity
percentage homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020520429A
Other languages
English (en)
Japanese (ja)
Other versions
JP7399852B2 (ja
JP2020530777A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039156 external-priority patent/WO2019005639A2/en
Publication of JP2020530777A publication Critical patent/JP2020530777A/ja
Publication of JP2020530777A5 publication Critical patent/JP2020530777A5/ja
Application granted granted Critical
Publication of JP7399852B2 publication Critical patent/JP7399852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520429A 2017-06-25 2018-06-22 多重特異性抗体とその作製及び使用方法 Active JP7399852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
US62/524,557 2017-06-25
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF

Publications (3)

Publication Number Publication Date
JP2020530777A JP2020530777A (ja) 2020-10-29
JP2020530777A5 true JP2020530777A5 (https=) 2022-02-07
JP7399852B2 JP7399852B2 (ja) 2023-12-18

Family

ID=64742644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520429A Active JP7399852B2 (ja) 2017-06-25 2018-06-22 多重特異性抗体とその作製及び使用方法

Country Status (10)

Country Link
US (1) US11787863B2 (https=)
EP (1) EP3645049A4 (https=)
JP (1) JP7399852B2 (https=)
KR (2) KR102763369B1 (https=)
CN (4) CN110831973B (https=)
AU (2) AU2018295118B2 (https=)
CA (1) CA3068045A1 (https=)
IL (2) IL313468A (https=)
SG (1) SG11201912864SA (https=)
WO (1) WO2019005639A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
US20250376531A9 (en) * 2017-06-25 2025-12-11 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
JP7592712B2 (ja) * 2019-11-06 2024-12-02 システィミューン， インク． ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
US20250346681A1 (en) * 2022-04-11 2025-11-13 Astrazeneca Ab T cell binding proteins
AU2023409023A1 (en) * 2022-12-20 2025-07-31 Ho'ola Therapeutics Inc. Combination therapies for the treatment of cancer
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002311919B8 (en) * 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2611814A1 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN104072613A (zh) * 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
ES2702315T3 (es) * 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
EP3060579A1 (en) * 2013-10-25 2016-08-31 Numab AG Bispecific constructs and their use in the treatment of various diseases
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof

Similar Documents

Publication Publication Date Title
JP2020530306A5 (https=)
JP2020530777A5 (https=)
JP2020529864A5 (https=)
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN117285641A (zh) 制导和导航控制蛋白及其制备和使用方法
JP2021519072A5 (https=)
JP2022551081A (ja) 癌処置のための多重特異性結合タンパク質
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
CN117222672A (zh) 抗cldn4-抗cd137双特异性抗体
HK40093821A (zh) 多特异性抗体及其制备和使用方法
HK40088417A (zh) 多特异性抗体及其制备和使用方法
HK40111322A (zh) 多特异性抗体及其制备和使用方法
HK40111323A (zh) 多特异性抗体及其制备和使用方法
Li et al. Advancing immunotherapy via multiple immune cells co-engagement
HK40097105A (zh) 双特异性抗体及其制备和使用方法
WO2025064498A1 (en) Affinity-modulated anti-cd45 x pd-1 and anti-cd43 x pd-1 bispecific antibodies to treat cancer and autoimmunity
NZ760913B2 (en) Multi-specific antibodies and methods of making and using thereof
TW202434635A (zh) 多特異性抗體及其醫藥用途
HK40109798A (zh) 制导和导航控制蛋白及其制备和使用方法
HK40097671A (zh) 制导和导航控制蛋白及其制备和使用方法
HK40097672A (zh) 制导和导航控制蛋白及其制备和使用方法
HK40018991A (en) Multi-specific antibodies and methods of making and using thereof
HK40019010A (en) Multi-specific antibodies and methods of making and using thereof